Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis

George R. Thompson, Janis E. Blair, Sharon Wang, Robert Bercovitch, Michael Bolaris, Dane Van Den Akker, Rodrigo Lopez, Arash Heidari, Antonino Catanzaro, Jose Cadenazuluaga, Peter Chin-Hong, Brad Spellberg, Royce Johnson

Research output: Contribution to journalArticle

6 Scopus citations


Coccidioidal meningitis (CM) has high morbidity, and adjunctive measures to improve outcomes are needed. Using an established multicenter retrospective cohort study of CM (N = 221), we found that patients receiving adjunctive corticosteroids had a significant reduction in secondary cerebrovascular events (P =.0049). Those with CM-associated cerebrovascular events (8%) may benefit from short-term corticosteroids.

Original languageEnglish (US)
Pages (from-to)338-341
Number of pages4
JournalClinical Infectious Diseases
Issue number2
StatePublished - Jul 15 2017



  • coccidioidomycosis
  • corticosteroids
  • meningitis
  • stroke.
  • vasculitis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Thompson, G. R., Blair, J. E., Wang, S., Bercovitch, R., Bolaris, M., Van Den Akker, D., Lopez, R., Heidari, A., Catanzaro, A., Cadenazuluaga, J., Chin-Hong, P., Spellberg, B., & Johnson, R. (2017). Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis. Clinical Infectious Diseases, 65(2), 338-341.